Changes for page Egalet Corporation

Last modified by Wilton Risenhoover on 2019/10/22 05:45
From version < 2.2 >
edited by Asif Farooqui
on 2019/10/22 04:17
To version < 3.1
edited by Wilton Risenhoover
on 2019/10/22 05:45
<
Change comment: There is no comment for this version

Summary

Details

Page properties
Author
... ... @@ -1,1 +1,1 @@
1 -XWiki.AsifF
1 +XWiki.wiltonio
Content
... ... @@ -2,8 +2,7 @@
2 2  {{toc/}}
3 3  {{/box}}
4 4  
5 -= =
6 -
5 +(% class="wikigeneratedid" id="H" %)
7 7  Egalet Corporation (EGLT) is a fully integrated specialty pharmaceutical company developing, manufacturing and commercializing innovative treatments for pain and other conditions. Given the need for acute and chronic pain products and the issue of prescription abuse, the company focused on bringing non-narcotic and abuse-deterrent (“AD”) opioid formulations to patients and physicians. Egalet is currently marketing ARYMO® ER (morphine sulfate) extended-release (“ER”) tablets, for oral use CII (“ARYMO ER”), SPRIX® (ketorolac tromethamine) Nasal Spray (“SPRIX Nasal Spray”), and OXAYDO® (oxycodone HCI, USP) tablets for oral use only—CII (“OXAYDO”).{{footnote}}https://fintel.io/doc/sec-eglt-egalet-10k-2018-march-16-17944{{/footnote}}
8 8  
9 9  ARYMO ER, an ER morphine product formulated with abuse-deterrent properties and approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, is its first product developed using its proprietary Guardian™ Technology. Egalet acquired, and became obligated to pay royalty payments under a preexisting license of, SPRIX Nasal Spray, the first and only approved nasal spray formulation of a nonsteroidal anti-inflammatory drug (“NSAID”), used for short‑term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. Egalet also licensed OXAYDO, an immediate-release (“IR”) oral formulation of oxycodone designed to discourage intranasal abuse, which is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
This site is funded and maintained by Fintel.io